Thrombolysis for acute ischemic stroke--our experiences as part of SITS-MOST.
Thrombolysis with intravenous recombinant tissue plasminogen activator (rtPA) is the first evidence based treatment for acute ischemic stroke, which aims to reduce the cerebrovascular lesion. At University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, thrombolytic therapy with intravenous rtPA (alteplase) (Actilyse) for acute ischemic stroke was introduced in 2004. We present our results referring to demographic, time logistics and clinical outcome data as part of SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy) and compare them with the results from other centers in Croatia and all other participating centers. Up to now, 56 patients (61% of male and 39% of female, average age 67 years) have been treated at our department with intravenous rt-PA (0.9 mg/kg body weight, maximum 90 mg), with 10% of the dose given as a bolus followed by 60-minute infusion. Our experiences with thrombolytic therapy with intravenous rt-PA (alteplase) (Actilyse) for acute ischemic stroke confirm the safety and the efficacy of this therapy.
Roje-Bedeković
Marina
M
University Department of Neurology, Reference Center for Neurovascular Disorders, Ministry of Health and Social Welfare of Republic of Croatia, Sestre milosrdnice University Hospital, Zagreb. mroje@mef.hr
Vargek-Solter
Vesna
V
Corić
Lejla
L
Sabolek
Karla
K
Breitenfeld
Tomislav
T
Supanc
Visnja
V
Demarin
Vida
V
D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator